Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ImmunityBio recently reported positive clinical data from its ANKTIVA (nogapendekin alfa inbakicept) program in non-small ...

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, patients received the agent via subcutaneous injection every three weeks ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...